Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-04-25
DOI
10.1002/jcph.1131
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
- (2018) Lene Jensen et al. DIABETES OBESITY & METABOLISM
- Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species
- (2017) Lene Jensen et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Novel strategies in the oral delivery of antidiabetic peptide drugs – Insulin, GLP 1 and its analogs
- (2017) Ruba Ismail et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014
- (2017) Ginger Carls et al. Diabetes Therapy
- Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014
- (2017) Ginger Carls et al. Diabetes Therapy
- 8. Pharmacologic Approaches to Glycemic Treatment
- (2016) DIABETES CARE
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel
- (2015) Christoph Kapitza et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- (2015) Jesper Lau et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
- (2013) E. R. Seaquist et al. DIABETES CARE
- Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
- (2010) Anne Flint et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
- (2009) E.J. Verspohl PHARMACOLOGY & THERAPEUTICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started